Invex Therapeutics (ASX: IXC) executive director and chief science officer Alex Sinclair joins Small Caps to discuss the company’s Evolve phase III trial which is now underway and evaluating its lead drug Presendin in patients with idiopathic intracranial hypertension (IHH).

IIH is a rapidly growing disease, with incidences rising 350% over the last 10 year.

Around 240 newly diagnosed IIH patients will be recruited to the trial which will be open at 40 sites around the world.

Articles:
https://smallcaps.com.au/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals/
https://smallcaps.com.au/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial/

For more information on Invex Therapeutics:
https://smallcaps.com.au/stocks/IXC/

Invex Therapeutics (ASX: IXC) executive director and chief science officer Alex Sinclair joins Small Caps to discuss the company’s Evolve phase III trial which is now underway and evaluating its lead drug Presendin in patients with idiopathic intracranial hypertension (IHH).
IIH is a rapidly growing disease, with incidences rising 350% over the last 10 year.
Around 240 newly diagnosed IIH patients will be recruited to the trial which will be open at 40 sites around the world.
Articles: <a href="https://smallcaps.com.au/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals/">https://smallcaps.com.au/invex-therapeutics-recruiting-iih-patients-nz-clinical-trial-regulatory-approvals/</a> <a href="https://smallcaps.com.au/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial/">https://smallcaps.com.au/invex-therapeutics-recruits-first-idiopathic-intracranial-hypertension-patient-presendin-trial/</a>
For more information on Invex Therapeutics: <a href="https://smallcaps.com.au/stocks/IXC/">https://smallcaps.com.au/stocks/IXC/</a>

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

Small Caps is Australia's #1 site for investor news &amp; information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of ASX listed small cap companies and financial market analysts.

Small Caps

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies.

The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts.

For more information visit: https://smallcaps.com.au/

Invex Therapeutics (ASX: IXC) rolls-out Evolve phase III trial for drug Presendin in IIH patients (w/ Alex Sinclair)

QMines (ASX: QML) chairman Andrew Sparke joins Small Caps to discuss the company's receipt of positive news from a pre-feasibility study (PFS) of its proposed development of the Mt Chalmers copper and gold mine in Queensland.

The Mt Chalmers study demonstrated that the project is a technically and financially robust and supports a stand-alone 1 million tonnes per annum process plan.

A significant milestone for QMines, the PFS result demonstrates Mt Chalmers is a

project with scale and potential for development.

The study also confirmed significant growth options within the Sulphide City, Scorpion and Woods Shaft deposits not currently in the mine plan.

Importantly, studies confirmed Mt Chalmers can be commercialised using industry standard treatment processes and techniques, providing low-cost development options at a time when gold and copper prices are surging.

Article:
https://smallcaps.com.au/qmines-study-viable-future-mt-chalmers-copper-gold-deposit/

For more information on QMines:
https://smallcaps.com.au/stocks/asx-qml/

QMines (ASX: QML) chairman Andrew Sparke joins Small Caps to discuss the company's receipt of positive news from a pre-feasibility study (PFS) of its proposed development of the Mt Chalmers copper and gold mine in Queensland.
The Mt Chalmers study demonstrated that the project is a technically and financially robust and supports a stand-alone 1 million tonnes per annum process plan.
A significant milestone for QMines, the PFS result demonstrates Mt Chalmers is a
project with scale and potential for development.
The study also confirmed significant growth options within the Sulphide City, Scorpion and Woods Shaft deposits not currently in the mine plan.
Importantly, studies confirmed Mt Chalmers can be commercialised using industry standard treatment processes and techniques, providing low-cost development options at a time when gold and copper prices are surging.
Article: <a href="https://smallcaps.com.au/qmines-study-viable-future-mt-chalmers-copper-gold-deposit/">https://smallcaps.com.au/qmines-study-viable-future-mt-chalmers-copper-gold-deposit/</a>
For more information on QMines: <a href="https://smallcaps.com.au/stocks/asx-qml/">https://smallcaps.com.au/stocks/asx-qml/</a>

QMines (ASX: QML) unveils robust PFS results for Mt Chalmers copper-gold mine (w/ Andrew Sparke)

International Graphite (ASX: IG6) managing director and chief executive officer Andrew Worland joins Small Caps to discuss the recent receipt of a $6.5 million grant from the Western Australian government.

The new grant takes the company’s total funding from the State’s Collie Just Transition Program to $8.5 million.

As well as the WA government support, International Graphite received $4.7 million in Federal funding as part of the Critical Minerals Development Program to support its mine-to-market graphite supply chain plans in WA.

The latest show of government support for the innovative battery materials developer will help advance the company's plans for a 4,000 tonnes per annum commercial-scale graphite micronising operation, at Collie, south of Perth.

The award is just the latest development this year in International Graphite's mine-to-market battery anode plans processing of graphite concentrate feed at Collie from its Springdale Graphite Project in WA’s south-east.

Earlier this year International Graphite received $1.3 million from the Australian Research and Development Tax Incentive Scheme for the 2023 financial year and raised $3 million in a placement, while the company will wrap up a $1 million SPP in the near future.

Articles:
https://smallcaps.com.au/international-graphite-capital-raising-advance-springdale-graphite-project/
https://smallcaps.com.au/international-graphite-secures-wa-funding-first-downstream-processing-plant/

For more information on International Graphite:
https://smallcaps.com.au/stocks/asx-ig6/

International Graphite (ASX: IG6) managing director and chief executive officer Andrew Worland joins Small Caps to discuss the recent receipt of a $6.5 million grant from the Western Australian government.
The new grant takes the company’s total funding from the State’s Collie Just Transition Program to $8.5 million.
As well as the WA government support, International Graphite received $4.7 million in Federal funding as part of the Critical Minerals Development Program to support its mine-to-market graphite supply chain plans in WA.
The latest show of government support for the innovative battery materials developer will help advance the company's plans for a 4,000 tonnes per annum commercial-scale graphite micronising operation, at Collie, south of Perth.
The award is just the latest development this year in International Graphite's mine-to-market battery anode plans processing of graphite concentrate feed at Collie from its Springdale Graphite Project in WA’s south-east.
Earlier this year International Graphite received $1.3 million from the Australian Research and Development Tax Incentive Scheme for the 2023 financial year and raised $3 million in a placement, while the company will wrap up a $1 million SPP in the near future.
Articles: <a href="https://smallcaps.com.au/international-graphite-capital-raising-advance-springdale-graphite-project/">https://smallcaps.com.au/international-graphite-capital-raising-advance-springdale-graphite-project/</a> <a href="https://smallcaps.com.au/international-graphite-secures-wa-funding-first-downstream-processing-plant/">https://smallcaps.com.au/international-graphite-secures-wa-funding-first-downstream-processing-plant/</a>
For more information on International Graphite: <a href="https://smallcaps.com.au/stocks/asx-ig6/">https://smallcaps.com.au/stocks/asx-ig6/</a>

International Graphite (ASX: IG6) wins major government and market backing (w/ Andrew Worland)

RocketBoots (ASX: ROC) chief executive officer Joel Rappolt joins Small Caps to discuss how the company's cutting-edge AI and machine learning technologies are reshaping profitability and customer service in the retail and banking sectors

RocketBoots leverages AI to optimise workforce planning and prevent loss, dramatically improving customer experiences and net promoter scores.

Joel shares insights into RocketBoots’ journey from their successful IPO to deploying transformative AI technologies in markets across the UK, EU and USA.

For more information on RocketBoots:
https://smallcaps.com.au/stocks/asx-roc/

RocketBoots (ASX: ROC) chief executive officer Joel Rappolt joins Small Caps to discuss how the company's cutting-edge AI and machine learning technologies are reshaping profitability and customer service in the retail and banking sectors
RocketBoots leverages AI to optimise workforce planning and prevent loss, dramatically improving customer experiences and net promoter scores.
Joel shares insights into RocketBoots’ journey from their successful IPO to deploying transformative AI technologies in markets across the UK, EU and USA.
For more information on RocketBoots: https://smallcaps.com.au/stocks/asx-roc/

Invex Therapeutics (ASX: IXC) rolls-out Evolve phase III trial for drug Presendin in IIH patients (w/ Alex Sinclair)

In 1 playlist(s)

Small Caps

Social links

Follow podcast

Recent clips